問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Digestive System Department

Division of Thoracic Medicine

更新時間：2023-09-19

蔡佳叡Tsai, Jia-Ruey
  • Principal Investigator
  • Clinical Trial Experience (year) 8 years

Recruiting Trial

20Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡佳叡

List

26Cases

2023-05-10 - 2025-04-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2024-04-01 - 2028-01-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2021-06-01 - 2028-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting8Sites

Recruiting3Sites

2020-12-15 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-06-01 - 2027-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-11-18 - 2024-12-31

Phase II

Completed
An Exploratory, Randomised, Double-blind, Parallel-Group, Placebo-Controlled Phase IIa Study to Assess the Analgesic Activity of PAX-1 in Patients with Persistent Cancer Pain.

  • Condition/Disease

    Persistent Cancer Pain

  • Test Drug

    PAX-1

Participate Sites
7Sites

Recruiting2Sites

Terminated5Sites

2022-09-01 - 2025-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting7Sites

Terminated1Sites

2026-04-01 - 2029-11-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

2023-07-07 - 2026-07-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-04-01 - 2028-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB